- Home
- AXSM vs CZR Comparison
AXSM vs CZR Comparison
Compare AXSM & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXSM
- CZR
- Stock Information
- Founded
- AXSM 2012
- CZR 1937
- Country
- AXSM United States
- CZR United States
- Employees
- AXSM N/A
- CZR N/A
- Industry
- AXSM Biotechnology: Pharmaceutical Preparations
- CZR Hotels/Resorts
- Sector
- AXSM Health Care
- CZR Consumer Discretionary
- Exchange
- AXSM Nasdaq
- CZR Nasdaq
- Market Cap
- AXSM 5.1B
- CZR 5.4B
- IPO Year
- AXSM 2015
- CZR 1989
- Fundamental
- Price
- AXSM $107.76
- CZR $28.03
- Analyst Decision
- AXSM Strong Buy
- CZR Strong Buy
- Analyst Count
- AXSM 15
- CZR 13
- Target Price
- AXSM $170.20
- CZR $44.23
- AVG Volume (30 Days)
- AXSM 655.3K
- CZR 5.6M
- Earning Date
- AXSM 05-05-2025
- CZR 04-29-2025
- Dividend Yield
- AXSM N/A
- CZR N/A
- EPS Growth
- AXSM N/A
- CZR N/A
- EPS
- AXSM N/A
- CZR N/A
- Revenue
- AXSM $432,157,000.00
- CZR $11,297,000,000.00
- Revenue This Year
- AXSM $63.52
- CZR $3.74
- Revenue Next Year
- AXSM $63.32
- CZR $2.51
- P/E Ratio
- AXSM N/A
- CZR N/A
- Revenue Growth
- AXSM 72.16
- CZR N/A
- 52 Week Low
- AXSM $64.11
- CZR $21.40
- 52 Week High
- AXSM $139.13
- CZR $45.93
- Technical
- Relative Strength Index (RSI)
- AXSM 46.37
- CZR 55.37
- Support Level
- AXSM $103.15
- CZR $26.72
- Resistance Level
- AXSM $120.00
- CZR $28.40
- Average True Range (ATR)
- AXSM 3.51
- CZR 1.19
- MACD
- AXSM 0.66
- CZR 0.20
- Stochastic Oscillator
- AXSM 29.45
- CZR 76.07
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About CZR Caesars Entertainment Inc.
Caesars Entertainment includes about 50 domestic gaming properties across the Las Vegas (49% of 2024 EBITDAR before corporate expenses) and regional (46%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2024. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform.